Patent ID: 9629903
Date: 2017-04-25
CPC Classifications: A61K,A61P,C07K,C12N,C12Y

Claim:
1. A method of treating hemophilia B in a human subject in need thereof, comprising intravenously administering to the subject multiple doses of about 50 IU/kg to about 100 IU/kg of a chimeric Factor IX (“FIX”) polypeptide comprising FIX and an FcRn binding partner (“FcRn BP”) at a dosing interval of about 10 days to about 14 days between two doses, wherein the FcRn BP comprises Fc or albumin, wherein the trough level of the plasma FIX activity after each administration is at least 3 IU/dL after six days, and wherein the administration treats the human subject by reducing the frequency of spontaneous bleeding.